Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR444336 in adults with microscopic colitis who are in clinical remission and currently receiving budesonide therapy. This is a Phase 2, randomized, double-blind, placebo-controlled study designed to assess whether SAR444336 can help maintain steroid-free clinical remission in this population. Participants will be randomly assigned to receive several subcutaneous injections of either SAR444336 or placebo while continuing their prescribed budesonide dose. The overall study duration is approximately 32 weeks, with primary outcomes measured up to week 24 and safety monitoring extending to week 28. During the study, participants will undergo regular assessments to monitor clinical remission status, drug plasma levels, and possible adverse events. Researchers will track treatment-emergent adverse events, anti-drug antibody development, and study withdrawal reasons. The trial includes close safety and efficacy monitoring, with the primary outcome focusing on sustained steroid-free remission up to week 24.
Actively Recruiting
Researchers are evaluating a new approach for adults with moderate to severe ulcerative colitis who need treatment with adalimumab. This Phase IV randomized trial compares standard care with a treat-to-target strategy that includes telemonitoring and patient education. The study aims to assess the impact of using home fecal calprotectin tests and e-monitoring combined with education on disease control by week 48. All participants will initially receive adalimumab with doses starting at 1608040 mg every other week until week 14, then 40 mg every other week until week 26. Dosage may be adjusted up to 80 mg every other week or 40 mg every week based on patient or investigator choice. In addition, patients may receive azathioprine or methotrexate alongside adalimumab until week 38. The study groups differ by follow-up method one group receives standard care with doctor visits every three months, while the other group has e-monitoring, home fecal calprotectin testing, and therapy education. Participants will be involved for about 144 weeks and complete regular assessments including endoscopic exams, clinical evaluations, quality of life surveys, and treatment adherence questionnaires. The study measures success primarily by endoscopic remission at week 48 and also tracks clinical remission, healing rates, patient satisfaction, hospitalizations, colectomies, and safety. Monitoring includes frequent e-monitoring questionnaires and fecal calprotectin testing at home. The trial also evaluates medication compliance and economic outcomes related to treatment.
Actively Recruiting
Inflammatory Bowel Disease IBD, including Crohns disease and ulcerative colitis, is a chronic condition affecting the digestive tract that is increasingly diagnosed in adolescents and young adults. This research aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity APA program on the quality of life for patients with IBD. The study focuses on evaluating changes after a 12-week APA intervention delivered via the MOOV application. Participants will take part in a 12-week remote APA program without a comparator group. The program is delivered through an app that guides physical activity tailored to the participants needs. Patient data will be compared before and after the intervention to assess the programs effects on quality of life and other health factors. During the study, participants will be assessed at the start and after 3 months of the APA program. Researchers will measure quality of life changes as the primary outcome, alongside secondary outcomes like anxiety, depression, fatigue, and IBD activity. The study will also evaluate feasibility, satisfaction, persistence of physical activity, and biological markers related to disease activity. Participation lasts at least 3 months, with continuous monitoring through the app.